Sam Brusco, Associate Editor11.09.23
Spineology announced that John Booth plans to retire from his role as the company’s CEO, effective November 10, 2023. He will also resign from the board of directors.
Brian Snider will replace him as CEO on November 13 and on the board. With almost twenty years of progressive leadership experience in the medical device industry, Snider was most recently the executive VP of marketing for Alphatec Spine (ATEC). Most recently, he oversaw ATEC’s Biologics, Cervical, and Thoracolumbar business units.
Prio to ATEC, he spent nine years at NuVasive, where he held senior level marketing roles in the Thoracolumbar business segment, including the flagship XLIF procedure.
"I am thrilled to join the Spineology team,” Snider told the press. “Spineology is a company with a unique procedural foundation that is backed with strong clinical data. I am confident that we will deliver growth and surgical advancement during this next phase. I would like to thank the Board for the opportunity to serve the Spineology team, the shareholders, and most importantly, our patients.”
"It has been a great privilege to work with a talented and passionate group of employees throughout the company, who together have advanced the field of ultra-minimally invasive spine surgery significantly over the company’s history," added John Booth. "I have every confidence that the Company will continue to grow and provide disruptive solutions under Brian’s leadership as the next CEO of Spineology."
Brian Snider will replace him as CEO on November 13 and on the board. With almost twenty years of progressive leadership experience in the medical device industry, Snider was most recently the executive VP of marketing for Alphatec Spine (ATEC). Most recently, he oversaw ATEC’s Biologics, Cervical, and Thoracolumbar business units.
Prio to ATEC, he spent nine years at NuVasive, where he held senior level marketing roles in the Thoracolumbar business segment, including the flagship XLIF procedure.
"I am thrilled to join the Spineology team,” Snider told the press. “Spineology is a company with a unique procedural foundation that is backed with strong clinical data. I am confident that we will deliver growth and surgical advancement during this next phase. I would like to thank the Board for the opportunity to serve the Spineology team, the shareholders, and most importantly, our patients.”
"It has been a great privilege to work with a talented and passionate group of employees throughout the company, who together have advanced the field of ultra-minimally invasive spine surgery significantly over the company’s history," added John Booth. "I have every confidence that the Company will continue to grow and provide disruptive solutions under Brian’s leadership as the next CEO of Spineology."